Citius Oncology Launches LYMPHIR, Completes $36 Million Financing
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 23 2025
0mins
Source: Newsfilter
- Product Launch: Citius Oncology launched LYMPHIR™ in the U.S. in December 2025, a novel immunotherapy for relapsed or refractory cutaneous T-cell lymphoma, marking the company's transition from pre-revenue to revenue-generating status, with an initial market estimated to exceed $400 million, indicating significant commercial potential.
- Successful Financing: The company completed $36 million in strategic financing during fiscal year 2025, including $18 million through a private placement and registered direct offering on December 10, 2025, strengthening its cash position to support the ongoing commercialization of LYMPHIR, ensuring operational stability for the future.
- International Market Expansion: Citius Oncology secured access to LYMPHIR in 19 markets across Southern Europe and the Middle East through Named Patient Programs, marking a preliminary success in the company's global strategy and expected to drive international revenue growth.
- Technological Collaboration: The company partnered with Verix to leverage its Tovana AI platform to enhance commercial targeting and field execution for LYMPHIR, which will not only optimize marketing strategies but also improve engagement with healthcare providers, accelerating product adoption in the market.
Analyst Views on CTOR
Wall Street analysts forecast CTOR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CTOR is 6.00 USD with a low forecast of 6.00 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.100
Low
6.00
Averages
6.00
High
6.00
Current: 1.100
Low
6.00
Averages
6.00
High
6.00
About CTOR
Citius Oncology, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing targeted oncology therapies. The Company’s lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. LYMPHIR is a targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL) indicated for use in Stage I-III disease after at least one prior systemic therapy. It is a recombinant fusion protein that combines the IL-2 receptor binding domain with diphtheria toxin fragments. The agent specifically binds to IL-2 receptors on the cell surface, causing diphtheria toxin fragments that have entered cells to inhibit protein synthesis. After uptake into the cell, the diphtheria toxin (DT) fragment is cleaved and the free DT fragments inhibit protein synthesis, resulting in cell death.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
